Los Angeles Capital Management LLC Has $1.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Los Angeles Capital Management LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 39.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,366 shares of the company's stock after buying an additional 8,920 shares during the period. Los Angeles Capital Management LLC owned approximately 0.05% of Protagonist Therapeutics worth $1,211,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PTGX. Creative Planning acquired a new position in shares of Protagonist Therapeutics in the 3rd quarter valued at approximately $338,000. Louisiana State Employees Retirement System bought a new position in Protagonist Therapeutics in the third quarter valued at approximately $1,282,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Protagonist Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock worth $95,000 after acquiring an additional 379 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Protagonist Therapeutics during the third quarter worth $1,512,000. Finally, New York State Teachers Retirement System acquired a new stake in shares of Protagonist Therapeutics during the third quarter worth $1,107,000. Institutional investors own 98.63% of the company's stock.

Insiders Place Their Bets

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares of the company's stock, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.40% of the company's stock.

Remove Ads

Protagonist Therapeutics Stock Down 0.5 %

Shares of NASDAQ:PTGX traded down $0.21 during midday trading on Wednesday, hitting $38.45. The stock had a trading volume of 1,509,646 shares, compared to its average volume of 698,969. The company has a market cap of $2.36 billion, a P/E ratio of 14.45 and a beta of 2.34. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $48.89. The business's 50-day simple moving average is $37.87 and its 200-day simple moving average is $41.76.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

PTGX has been the subject of a number of research reports. JPMorgan Chase & Co. increased their target price on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Tuesday. Wedbush reaffirmed an "outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, February 21st. StockNews.com lowered Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. JMP Securities reaffirmed a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Finally, The Goldman Sachs Group lowered their price objective on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, February 24th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $55.89.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.